Research Analysts Set Expectations for Tandem Diabetes Care, Inc.’s Q4 2025 Earnings (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Leerink Partnrs upped their Q4 2025 earnings estimates for shares of Tandem Diabetes Care in a research report issued to clients and investors on Friday, May 3rd. Leerink Partnrs analyst M. Kratky now expects that the medical device company will earn $0.06 per share for the quarter, up from their prior forecast of $0.05. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.62) per share.

TNDM has been the topic of several other reports. Citigroup upped their price target on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Stifel Nicolaus raised their price target on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Piper Sandler reaffirmed an “overweight” rating and set a $50.00 price objective (up previously from $35.00) on shares of Tandem Diabetes Care in a research report on Friday, May 3rd. SVB Leerink upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $34.00 to $45.00 in a research note on Thursday, April 25th. Finally, Wells Fargo & Company upgraded Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $21.00 to $45.00 in a research note on Monday, April 29th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and an average price target of $43.80.

Tandem Diabetes Care Trading Up 1.1 %

NASDAQ:TNDM opened at $44.00 on Monday. The company has a market cap of $2.84 billion, a PE ratio of -20.28 and a beta of 1.10. The business’s 50 day moving average is $32.91 and its two-hundred day moving average is $26.53. The company has a quick ratio of 3.01, a current ratio of 3.81 and a debt-to-equity ratio of 1.43. Tandem Diabetes Care has a 52 week low of $13.82 and a 52 week high of $47.00.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The company had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TNDM. Sei Investments Co. boosted its position in Tandem Diabetes Care by 125.8% during the 1st quarter. Sei Investments Co. now owns 17,349 shares of the medical device company’s stock worth $614,000 after acquiring an additional 9,666 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in shares of Tandem Diabetes Care during the first quarter valued at about $1,335,000. Lisanti Capital Growth LLC lifted its holdings in Tandem Diabetes Care by 65.1% in the first quarter. Lisanti Capital Growth LLC now owns 174,830 shares of the medical device company’s stock worth $6,191,000 after purchasing an additional 68,935 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in Tandem Diabetes Care by 49.0% in the first quarter. Oppenheimer Asset Management Inc. now owns 40,380 shares of the medical device company’s stock worth $1,430,000 after purchasing an additional 13,277 shares during the period. Finally, SG Americas Securities LLC bought a new position in Tandem Diabetes Care in the 1st quarter valued at about $5,227,000.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.